This post was originally published on this site
The company has been working on developing vaccines for skin cancer, flu and respiratory syncytial virus (RSV) using its mRNA technology, which if approved would significantly help Moderna (NASDAQ:MRNA) that currently relies heavily on its COVID-19 shot.
The COVID vaccine maker said it will open new offices in California and Seattle, which will provide technology solutions across the company, and its Genomics unit will expand to south San Francisco.
Moderna had about 3,900 full-time employees as of Dec. 31, according to a regulatory filing.
